Microvascular Therapeutics (MVT) is presenting at Life Science Summit on October 11th, in New York.
Microvascular Therapeutics’ Post
More Relevant Posts
-
Our Head of Translational Medicine Kenneth Crook will be presenting Engimmune's AI-guided platform technologies for soluble TCR drug development at Immuno 2024 on April 25-26. In this video, we get his perspective on current trends in immuno-oncology and on how specTR molecules (specificity- and affinity-enhanced soluble TCR engagers) can address key challenges in the treatment of solid tumours. https://lnkd.in/eP7XteCS
Dive into the future of immuno-oncology with Kenneth Crook, Head of Translational Medicine at Engimmune Therapeutics. Gain exclusive insights into his upcoming presentation at Immuno 2024 and discover what's on the horizon for this dynamic field! 🧬 Meet Kenneth and be part of the conversation: https://hubs.la/Q02rsR310 #OGImmuno #Immuno24
To view or add a comment, sign in
-
Interesting perspective on future immunotherapeutics
Dive into the future of immuno-oncology with Kenneth Crook, Head of Translational Medicine at Engimmune Therapeutics. Gain exclusive insights into his upcoming presentation at Immuno 2024 and discover what's on the horizon for this dynamic field! 🧬 Meet Kenneth and be part of the conversation: https://hubs.la/Q02rsR310 #OGImmuno #Immuno24
To view or add a comment, sign in
-
Join us for this webinar on April 4th to learn more about the key considerations during the scale-up and manufacturing of nanoparticles for use in therapeutics.
In our upcoming webinar, Diana Dehaini, PhD, Project Manager & Technical Sales Scientist at nanoComposix | Fortis Life Sciences, will go over the key steps and considerations involved in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. During the presentation, we will navigate the journey from research to commercialization and more. Register today: https://hubs.li/Q02nCGvj0 Sponsored by nanoComposix | Fortis Life Sciences
To view or add a comment, sign in
-
Today, in our CEO and Chairman’s letter to stockholders, Coya announced that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications expected to be validated in the clinic. We recognize the historical challenges faced by pharma companies looking to address the massive problem that AD is posing to patients, families, and the healthcare system. Yet, researchers have shown that ALS, FTD, PD, and AD share common features, including neuroinflammation and catastrophic neuronal loss that leads to cognitive or motor dysfunction through the complex interplay of the body’s immune system and dysfunctional anti-inflammatory Tregs. We believe the traditional “one disease – one target - one drug” approach might not be the most appropriate framework for neurodegenerative disorders and may be partly responsible for the lack of available and truly effective treatments View our updated pipeline here: https://bit.ly/3HFANFN #Science #NeurodegenerativeDiseases #Biotech
To view or add a comment, sign in
-
Missed out on this year's #ASMS conference? That doesn’t mean you have to miss out on the exciting science we shared! Check out this poster presented by Jeremiah Bowers, based on a collaboration with MOMA Therapeutics. By leveraging cutting-edge proteomic technologies and mass spectrometry workflows developed by Momentum, Bowers and colleagues were able to identify and characterize several covalent cysteine modifiers active against cancer-driving helicases. Their research demonstrates the power of mass spec covalent binding screening, modification mapping, and occupancy calculations in taking a project from screening to hit characterization with unmatched efficiency. Want to learn more about this project? Request the full poster here: https://lnkd.in/e6GFCEvW #CancerResearch #DrugDiscovery #RapidFireMS, #OrbitrapAscend #Covalent #Chemoproteomics #Chemicalbiology
To view or add a comment, sign in
-
Headhunting Talented Individuals within Clinical Operations & Clinical Development for growing organizations across the US & Europe
What a super effort from Memo Therapeutics after recently securing their Series B round of funding totalling a whopping $27.67m! 👏💰 This valuable money will be used to begin a clinical trial studying a new treatment approach for preventing infection in kidney transplant patients. 💊 It's very exciting news as there is potential to revolutionize the lives of so many transplant patients around the world🙂🌏 We all like to hear a good news story, right? It always amazes me continually learning of the amazing work that is going on behind the scenes to shape a better future for all - Top work! #MedicineInnovation #Innovation #MemoTherapeutics #ClinicalResearch #ClinicalResearchProfesionals #BetterFuture #Biotechnology #KidneyTransplant #ClinicalTrial #ElixirAssociates
Memo Therapeutics raises $27.67m for kidney transplant infection trial
To view or add a comment, sign in
-
M4205 (IDRX-42): A Selective KIT Inhibitor With a Non-Classical Hinge Binder for the Treatment of Gastrointestinal Stromal Tumors | https://lnkd.in/gyhAzeXT M4205 (IDRX-42) is a highly selective type II receptor tyrosine kinase (RTK) inhibitor of KIT, discovered by Merck KGaA, Darmstadt, Germany and currently being developed by IDRx. KIT has been difficult to target effectively due to its high propensity for both mutations in the KIT gene and within the ATP-binding pocket leading to the recurrence of locally advanced disease. This molecule is a notable example of kinase selectivity achieved with a non-classical hinge binder. M4205 (IDRX-42) has received an Orphan Drug designation and is currently being evaluated in a Ph. I/Ib FIH trial for GIST, one of the most common mesenchymal neoplasms in the GI tract. This article highlights the unmet need for selective KIT inhibitors to treat GIST, the discovery and development story of M4205 (IDRX-42), how a non-classical hinge-binder is leveraged, translatable strategies for de-risking hERG liabilities, and recently released preliminary clinical trial data. Article | https://lnkd.in/gyhAzeXT
M4205 (IDRX-42)
drughunter.com
To view or add a comment, sign in
-
Accomplished Board Member | Expert healthcare industry knowledge from scientific and commercial perspectives
Headed home from the 15th International Congress, after 2 full days of interesting and innovative presentations! The future is getting much brighter for patients with MPN, with many novel new therapeutics on the horizon! #MPN #clinicaltrials #patientsfirst
To view or add a comment, sign in
-
[BLOG POST] Dive Deeper into the Future of Therapeutics! Get ready for the next part of our ground-breaking blog series - 'The Future is Non-Viral,' where we delve even further into the exciting realm of therapeutic advancements. In this sequel, we continue to explore the insights shared by Ken LeClair, Chair of RoslinCT’s Scientific Advisory Board, uncovering the transformative potential of non-viral vector alternatives. Discover how cutting-edge cellular reprogramming techniques are revolutionizing the field and learn about the latest advancements that are reshaping tomorrow's therapies. Read the blog post: https://lnkd.in/ehQxp_an #TherapeuticDelivery #SABPerspectives #Roslinsights
To view or add a comment, sign in
-
Exciting news in the world of medical innovation! Bayer's Parkinson's stem-cell-derived therapy, bemdaneprocel, is making significant strides towards a brighter future. The phase 1 data has just been unveiled, confirming that this stem-cell-derived therapy has successfully achieved its crucial safety milestones. Developed under Bayer's subsidiary, BlueRock Therapeutics, this therapy aims to transform the lives of those with Parkinson's. The journey began in 2021 with a groundbreaking phase 1 trial. The mission? To assess the safety and tolerability of surgically transplanting dopamine-producing cells into the brains of 12 Parkinson's patients. The focus was on understanding adverse events and tissue growth post-transplantation. The results are beyond promising! Bayer's preliminary assessment in June hinted at the therapy's safety, and now, they've officially confirmed that all 12 patients demonstrated safety and tolerability. #nextphase #medicaladvances #parkinsonsresearch
To view or add a comment, sign in
342 followers